Author: kassiemei125

SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 6 June 2022, an Investigational New Drug application (“IND”, for neuromyelitis optica spectrum disorder (“NMOSD”)) for SN1011 has been filed with and accepted by the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration of China (the “NMPA”). The Company plans to initiate the Phase II clinical study in China upon approval of the ... Read more